The identification of ELF5 as a potential biomarker is quite a novel finding and may be justified by a recent study documenting demethylation in the promoter regions of ELF5 when modelling chronic submergence damage that leads to an IBD state (Rees et al. 2022). This evidence concerns the gene ELF5 and inflammatory bowel disease.